With a market cap of several hundred million, to call DiscGenics a “Startup” isn’t exactly true. This growth stage company has their eye on becoming a blockbuster (injectable) drug company. Can a new cell line (discogenic cells) revolutionize the way that spinal disc disease is treated and regenerate a failing disc?

“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of DiscGenics. DiscGenics is committed to revolutionizing the way millions of patients suffering from chronic back pain will be treated through a focus on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. They are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex e ...